Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from... Read more.
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify... Read more.
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
Rack-Level ZT Platform Powered by NVIDIA GB200 Grace Blackwell Superchips Enables Trillion-Parameter Inference and Training for Generative AI SECAUCUS, N.J.–(BUSINESS... Read more.
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
Integration enhances the Denodo Platform, providing enterprise customers with faster, more secure, and fully scalable AI capabilities PALO ALTO, Calif.–(BUSINESS... Read more.
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
At the office opening today, Ángel Viña, CEO of Denodo will be joined by Dr. Shaikha Dheya Bint Ebrahim Al Khalifa and representatives from Google Cloud RIYADH,... Read more.
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
57% of patients treated with IMFINZI were alive at three years in ADRIATIC Phase III trial WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the... Read more.
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
– In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk... Read more.
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
– In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk... Read more.
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca’s ENHERTU is the first HER2 directed medicine and antibody drug conjugate to demonstrate clinically... Read more.
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the United States and Europe
Combination of AI-enabled clinical trial matching, genetic testing, symptom management, psychosocial, and lifestyle support addresses physical and mental health... Read more.